These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9555153)

  • 21. A novel therapeutic approach to dyslipidemia.
    Clearfield MB
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S16-20. PubMed ID: 12572626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cholesterol: blood levels or total risk as a guide to preventive treatment?].
    Mathes P
    Z Kardiol; 2004; 93 Suppl 2():II16-20. PubMed ID: 15021991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.
    Preiss D; Sattar N
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):815-28. PubMed ID: 19067719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lowering cholesterol: how low is low enough?].
    Czuriga I; Edes I
    Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lipid control in diabetic patients in Extremadura (Spain)].
    Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
    Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The action of 1,4-dicaffeylquinic acid on the lipid fractions of the blood in atherosclerosis].
    Caruzzo C; Carnaghi R; Enrico-Bena L; De Marco G
    Minerva Med; 1969 Nov; 60(91):4514-8. PubMed ID: 5357297
    [No Abstract]   [Full Text] [Related]  

  • 28. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 2006 Sep; 150(39):2127-30. PubMed ID: 17059084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stain therapy and reduced incidence of stroke. Implications of cholesterol-lowering therapy for cerebrovascular disease.
    Gotto AM
    Arch Intern Med; 1997 Jun; 157(12):1283-4. PubMed ID: 9201001
    [No Abstract]   [Full Text] [Related]  

  • 31. Regression of coronary artery disease as a result of intensive lipid-lowering therapy.
    N Engl J Med; 1991 Apr; 324(16):1133-5. PubMed ID: 2008188
    [No Abstract]   [Full Text] [Related]  

  • 32. Lowering cholesterol in patients with coronary heart disease: are we ready yet?
    Barrett-Connor E
    Circulation; 1997 Dec; 96(12):4124-5. PubMed ID: 9416875
    [No Abstract]   [Full Text] [Related]  

  • 33. [The effect of a reduction in plasma cholesterol on the evolution of coronary disease].
    Fernández-Avilés F; García-Morán E
    Rev Esp Cardiol; 1995; 48 Suppl 5():43-51. PubMed ID: 7494940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Abnormal lipid metabolism and coronary insufficiency].
    Murakami M; Sekimoto H; Tanaka I; Seo M; Takegoshi T
    Saishin Igaku; 1970 Jan; 25(1):101-9. PubMed ID: 5450347
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of clofibrate and dextrothyroxine singly and in combination on serum lipids.
    Best MM; Duncan CH
    Arch Intern Med; 1966 Aug; 118(2):97-102. PubMed ID: 5329616
    [No Abstract]   [Full Text] [Related]  

  • 36. [Correction of disturbances of the relation between the levels of lipids and the products of their peroxidation in patients with coronary atherosclerosis and myocardial infarction].
    Kalmykova VI; Burlakova EB
    Sov Med; 1982; (4):3-7. PubMed ID: 7101054
    [No Abstract]   [Full Text] [Related]  

  • 37. [Therapeutic agents for lipid metabolism disorders--with special reference to arterial diseases].
    Murakami M; Sekimoto H; Nagai T; Nakata I; Takekoshi T
    Nihon Rinsho; 1970 Mar; 28 Suppl():696-9. PubMed ID: 5430846
    [No Abstract]   [Full Text] [Related]  

  • 38. The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease.
    Pioruńska-Stolzmann M; Pioruńska-Mikołajczak A
    Pharmacol Res; 2001 Apr; 43(4):359-62. PubMed ID: 11394370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effect of halofenate on serum lipids.
    Aronow WS; Vangrow J; Pagano J; Khemka M; Vawter M; Papageorge's NP
    Curr Ther Res Clin Exp; 1974 Sep; 16(9):897-903. PubMed ID: 4214664
    [No Abstract]   [Full Text] [Related]  

  • 40. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease.
    Thompson GR; Hollyer J; Waters DD
    Curr Opin Lipidol; 1995 Dec; 6(6):386-8. PubMed ID: 8750253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.